WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 15, 1160-1174. Review Article ISSN 2277– 7105

REVIEW ARTICLE ON ICH GUIDELINES (INTERNATIONAL COUNCIL OF HARMONISATION)

***Ashish S. Kanthale, Vaishnavi G. Darne and Farheen A. Shah**

Jagadambha Institute of Pharmacy and Research, Kalamb, Maharashtra, India.

Article Received on
21 July 2023,

Revised on 11 August 2023,
Accepted on 31 August 2023

DOI: 10.20959/wjpr202315-29572

***Corresponding Author**
Ashish S. Kanthale
Jagadambha Institute of Pharmacy and Research, Kalamb, Maharashtra, India.

ABSTRACT

Harmonization of nonsupervisory conditions was initiated by the European Community(EC), in the 1980s, the EC moved towards the development of a single request for medicinal. At the same time there were bilateral conversation between Europe, Japan and the US on possibilities for harmonization. ICH nonsupervisory authorities are among the first to estimate new chemical realities and new products attained from biotechnology. ICH provides colorful guidelines which are distributed into four order, Quality guidelines, safety guidelines, efficacity guidelines and multidisciplinary guidelines. The major end of ICH To achieve lesser harmonization in the interpretation and operation of specialized guidelines for the enrollment of new active substances or products attained by biotechnology by its members; to ameliorate the effectiveness of global medicine development; to reduce spare studies; and to ameliorate pharmacovigilance conditioning and quality assurance. In every Active Pharmaceutical component, contamination is present. In pharmaceutical assiduity, chastity profile is important factor as well as contamination profile is important and obligatory according to Regulatory authority.

KEYWORDS: *ICH, Impurity, QSEM, harmonization, Pharmaceutical.*

INTRODUCTION

At the first ICH Steering Committee(SC) meeting of ICH the Terms of Reference were agreed and it was decided that the motifs named for harmonisation would be divided into Safety, Quality and Efficacy to reflect the three criteria which are the base for approving and authorizing new medicinal products.[1]

The birth of ICH took place at a meeting in April 1990, hosted by EFPIA in Brussels. Representatives of the nonsupervisory agencies and assiduity associations of Europe, Japan and the US met, primarily, to plan an International Conference and terms of reference of ICH.

First decade saw significant progress in the development of triplex ICH Guidelines on Safety, Quality and Efficacy motifs. Work was also accepted on a number of important multidisciplinary motifs, which included MedDRA (Medical Dictionary for Regulatory Conditioning) and the CTD (Common Technical Document) For two decades the ICH process has achieved important success. This success is attributed not only to a process of scientific agreement developed between assiduity and nonsupervisory experts, but also to the commitment of the nonsupervisory parties to apply the ICH triplex Harmonized Guidelines and recommendations. Throughout the alternate decade the development of ICH Guidelines continued, but with further attention given to the need to maintain formerly being Guidelines as wisdom and technology continued to evolve. Entering into its third decade of exertion, ICH's attention is directed towards extending the benefits of harmonisation beyond the ICH regions.

Mission

- ICH reduced the duplication of testing carried out during the exploration and development of new mortal drugs. ICH’s charge is to achieve lesser harmonisation in the interpretation and operation of specialized guidelines and its conditions for pharmaceutical product enrolment.[2]
- ICH is a unique undertaking that brings together the medicine nonsupervisory authorities and the pharmaceutical assiduity of Europe, Japan and the United States.
- Regulatory harmonisation offers numerous direct benefits to both nonsupervisory authorities and the pharmaceutical assiduity with salutary impact for the protection of public health. crucial benefits include precluding duplication of clinical trials in humans and minimizing the use of beast testing without compromising safety and effectiveness.

ORGANISATION

Organisation of ICH

Steering committee.



Figure 1: Various organisations of ICH.

Steering committee

The ICH Steering Committee (SC) is the governing body that oversees the harmonisation conditioning. Since its establishment in 1990, each of its six mentors (EU, EFPIA, MHLW, JPMA, FDA, PhRMA) has had two seats on the SC. Other parties have a significant interest in ICH and have been invited to nominate spectators to the SC. The three spectators are the World Health Organization (WHO), Health Canada and the European Free Trade Association (EFTA). The IFPMA participates as a nonvoting member of the SC.[3]

- WHO (World Health Organisation) Health Canada
- EFTA (European Free Trade Association)
- IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)
- PhRMA (Pharmaceutical Research and Manufacturers of America)
- EU (European Union)
- EFPIA (European Federation of Pharmaceutical diligence and Associations)
- MHLW (Ministry of Health, Labour and Welfare)
- JPMA (Japan Pharmaceutical Manufacturers Association)
- FDA (US Food and Drug Administration).

Global Cooperation Group

The Global Cooperation Group (GCG) was firstly formed as a council of the ICH Steering Committee in 1999 in response to a growing interest in ICH Guidelines beyond the three ICH regions.[4] Many times, latterly, recognising the need to engage laboriously with other

harmonisation enterprise, representatives from five Regional Harmonisation enterprise (RHIs) were invited to share in GCG conversations, videlicet, APEC, ASEAN, EAC, GCC, PANDRH and SADC. A farther expansion of the GCG was agreed in 2007 and controllers were invited from countries with a history of ICH Guideline perpetration and/ or where major product and clinical exploration are done (Australia, Brazil, China, Chinese Taipei, India, Republic of Korea, Russia and Singapore).

MedDRA Management Board

The MedDRA Management Board, appointed by the ICH Steering Committee, has overall responsibility for direction of MedDRA, an ICH standardised dictionary of medical language. The Board oversees the exertion of the MedDRA "conservation and Support Services Organisation" (MSSO), which serves as the repository, maintainer, innovator and distributor of MedDRA. The Management Board is composed of the six ICH Parties (EU, EFPIA, MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, the Health Canada and the WHO (as Observer). The IFPMA acts as an on- voting observer on the Management Board and chairs the Board.[5]

Secretariat

The ICH Secretariat is located in Geneva, Switzerland. Its staff member is responsible for day- to- day operation of ICH, videolike medications for, and attestation of, meetings of the Steering Committee and its Working Groups. The ICH Secretariat also provides executive support for the ICH Global Cooperation conditioning and the ICH MedDRA Management Board.[6]

CO-ORDINATORS

Abecedarian to the smooth handling of ICH has been the designation, by each of the six co-sponsors, of an ICH fellow to act as the main contact point with the ICH Secretariat.[7] fellow ensure proper distribution of ICH documents to the applicable persons from their party (SC members, Content Leaders, Experts) and are responsible for proper follow up on conduct by their separate party within assigned deadlines.

Working Groups

For each of the specialized motifs which have been named for harmonisation in the first phase of conditioning, the SC appointed a Working Group to review the differences in conditions between the three regions and develop scientific agreement needed to attune those

differences. Working groups don't have a fixed" class" but each of the six parties have nominated a Topic Leader (and, constantly, a Deputy Topic Leader) as the contact for the content. The spectators to ICH, the Pharmacopoeia authorities and representatives from the tone- drug assiduity and the general assiduity have been invited to share in colourful working groups.[8]

There are several different types of ICH working groups that can be linked

- EWG Expert Working Group is charged with developing a harmonised guideline that meets the objects in the Concept Paper and Business Plan.
- IWG perpetration Working Group is assigned to develop Q&A's to grease perpetration of being guidelines.
- Informal Working Group Is formed previous to any sanctioned ICH harmonisation exertion with the objects of developing/ finishing a Concept Paper, as well as developing a Business Plan.
- Discussion Group Is a group established to bandy specific scientific considerations or views i.e., Gene remedy Discussion Group (GTDG), and ICH & Women Discussion Group.[9]

Why International Conference on Harmonisation (ICH)

Trade battles: Trade enterprise played a crucial part in the conformation of the ICH. In the medial and late 1980s, the US and Japan began trade addresses that included discussion of opening up the Japanese request for US medicinal. In response, the European Commission strengthened its resoluteness to establish a single EU standard for medicine blessings in order to be competitive with Japan and the US in transnational trade accommodations. The International Federation of Pharmaceutical Manufacturers' Associations responded to this contending trade enterprise by organising meetings between the EU, Japan and the US.[10]

Faster approval: the driving force behind ICH is the pharmaceutical assiduity. Prior to ICH, a transnational company was needed to conduct a variety of studies and follow different government regulations in order to get its new product approved for patient use in different countries. The assiduity was interested in streamlining this process in order to reduce development costs and reduce the time to get medicines to request. These changes would allow trade name medicinal companies to reap lesser gains from a medicine because a shorter

part of the patent protection period is spent in there-marketing phase. The patent timepiece begins ticking from the time that companies file an operation for patent, so the hastily the medicine can get to request, the longer the exclusive deals period.[11]

ICH Guidelines for impurity profiling

It's now getting an important critical attention from nonsupervisory authorities. The International Conference on Harmonisation has published colourful guidelines on contaminations in medicine substances and medicine products as well as residual cleaners.

1) Q1A- "stability testing of new medicine substances and products"
2) Q3A(R2)- "contaminations in New Drug Substances"
3) Q3B (R2)- "contaminations in New Drug Products"
4) Q3C(R5)- "contaminations Guidelines for Residual cleaners".[12]

Regulatory Guidelines on contamination

International Conference on Harmonisation guidance of Technical Conditions for Registration of medicinal for mortal Use is inscribed by The United States Food and Drug Administration (FDA).

The FDA has the assigned responsibility of icing the safety and effectiveness of medicines. The colourful nonsupervisory guidelines regarding contaminations are as follows:

1 ICH guidelines — stability testing of new medicine substances and products" -Q1A
2 ICH guidelines — contaminations in New Drug Substances Ⅱ- Q3A
3 ICH guidelines — contaminations in New Drug Products Ⅱ- Q3B
4 ICH guidelines — contaminations Guidelines for residual cleaners Ⅱ- Q3C
5 US- FDA guidelines — NDAs- contaminations in New Drug Substances Ⅱ
6 US- FDA guidelines — ANDAs – contaminations in New Drug Substances Ⅱ
7 Australian nonsupervisory guideline for tradition drugs, remedial Governance Authority (TGA), Australia.-

REMEDIES TO PREVENT THE IMPURITIES INPHARMACEUTICAL PRODUCTS

Some of the remedies to help the contaminations in pharmaceutical products are listed below:

- Control of critical factors during the manufacturing of any product; which affect the product.

- Extreme functional care should be taken while handling the outfit's, ministries, reactors and other tools that by any mean due to the functional exertion, contamination shouldn't be entered into the product.
- The wet cutlet should be completely washed to remove all unwanted chemical including the residual detergents.
- In the specification, maximum possible contaminations should be specified with strict limits for the better- quality products.
- Time to time the specifications of medicine substances and medicine products should be studied and revised for specific contamination profiling and should be made strict for contamination acceptance criteria.
- During logical system development and confirmation study of any medicine substance and medicine product, the system parameters should be optimized in such a way that the system can resolve maximum number of contaminations which will help the synthetic druggist to ameliorate the synthetic process.
- Stability study should be carried out methodically and strictly for the identification of declination products and to fix the shelf life of medicine substances and medicine products.
- Stress study should be performed for any medicine substance or medicine product to handle the transportation related issues duly.
- Packaging care should be taken for the humidity/ light/ terrain/ stress sensitive accoutrements.
- Regulatory authorities should come stricter before giving any license or authorization for any product to be vended in any regulated request.
- Before giving any blessing related to FDA, for any pharmaceutical product to any company, the authorities should ensure the total compliance of the manufacturing point and product, as this is the matter related to mortal health and it cannot be taken in veritably casual way. However, also the medicinal diligence can get relieve of this burning issue of contaminations at major extent, if some of the listed remedies are enforced seriously and rigorously.[14]

The ICH guidelines are covered under four headings under the acronym QSEM – Quality, Safety, Efficacy and Multidisciplinary

(a) Quality guidelines: These guidelines cover the areas of quality of medicine products similar as contamination testing and stability studies and a flexible approach to quality on the base of GMP threat operation.

b) Safety guidelines: They help to descry implicit pitfalls similar as genotoxicity, carcinogenicity and nephrotoxicity.

For illustration, the ICH came up with an non-clinical test methodology to estimate QT interval extension which is presumably the most significant reason why medicines have been withdrawn in recent times.

c) Efficacy guidelines: These guidelines give guidance about designing, conducting, safety aspects and reporting of clinical trials for pharmaceutical products. new medicine products deduced from biotechnology and genomic/ pharmacogenetic ways for targeted medicine delivery are also covered.

d) Multidisciplinary guidelines: motifs in the pharmaceutical field that don't fit into any of the below orders are covered under this area. This guideline also includes details of (MedDRA), CTD and norms similar as electronic norms for the Transfer of Regulatory Information (ESTRI).

List of ICH guidelines

QUALITY GUIDELINES

Q1A-Q1F: Stability

Q2: Analytical Validation

Q3A-Q3D: Impurities

Q4-Q4B: Pharmacopoeias

Q5A-QSE: Quality of Biotechnological Products

Q6A-Q6B: Specifications

Q7: Good Manufacturing Practice

Q8: Pharmaceutical Development

Q9: Quality Risk Management

Q10: Pharmaceutical Quality System

Q11: Development and Manufacture of Drug Substances

Q12: Lifecycle Management

Q13: Continuous Manufacturing of Drug Substances and Drug Products

Q14: Analytical Procedure Development.

SAFETY GUIDELINES

S1A-S1C: Carcinogenicity Studies

S2: Genotoxicity Studies

S3A-S3B: Toxicokinetic and Pharmacokinetics

S4: Toxicity Testing

S5: Reproductive Toxicology

S6: Biotechnological Products

S7A-S7B: Pharmacology Studies

S8: Immunotoxicology Studies

S9: Nonclinical Evaluation for Anticancer Pharmaceuticals

S10: Photo safety Evaluation

S11: Nonclinical Paediatric Safety.

EFFICACY GUIDELINES

E1: Clinical Safety for Drugs used in Long-Term Treatment

E2A-E2F: Pharmacovigilance

E3: Clinical Study Reports

E4: Dose-Response Studies

E5: Ethnic Factors

E6: Good Clinical Practice

E7: Clinical Trials in Geriatric Population

E8: General Considerations for Clinical Trials E.g., Statistical Principles for Clinical Trials

E10: Choice of Control Group in Clinical Trials

E11: Clinical Trials in Paediatric Population

E12: Clinical Evaluation by Therapeutic Category

E14: Clinical Evaluation of QT

E15: Definitions in Pharmacogenetics/Pharmacogenomics

E16: Qualification for genomic biomarkers

E17: Multi-Regional Clinical Trials

E18: Genomic Sampling.

MULTIDISCIPLINARY GUIDELINES

M1: MedDRA Terminology

M2: Electronic Standards

M3: Nonclinical Safety Studies

M4: Common Technical Document.

M5: Data Elements and Standards for Drug Dictionaries

M6: Gene Therapy

M7: Mutagenic impurities

M8: Electronic Common Technical Document (eCTD)

M9: Biopharmaceutics Classification System-based Biowaivers

M10: Bioanalytical Method Validation.[15]

Process of ICH Harmonisation

1. Formal ICH Procedure

The procedure is initiated with the countersign by the SC of a Concept Paper and Business Plan. An Expert Working Group (EWG) with class as specified by the Concept Paper is latterly established.[9]

The EWG works to develop a draft Guideline and bring it through the colourful way of the procedure which crown in Step 5 and the perpetration in the ICH regions of a Harmonised triplex Guideline.

- Step1: Consensus structure The EWG works to prepare a agreement draft of the specialized document, grounded on the objects set out in the Concept Paper. Work is conducted via-mail, teleconferences and web conferences. However, the EWG will also meet face- to- face at the biannual SC meetings, If championed by the SC. Interim reports on the progress of the draft are made to the SC on a regular base. When agreement on the draft is reached among all six party EWG members, the EWG will subscribe the Step 1 Experts subscribe- off distance. The Step 1 Experts Specialized Document with EWG autographs is also submitted to the Steering Committee to request relinquishment under Step 2 of the ICH process.
- Step 2a:Evidence of six- party agreement on the Technical Document Step 2a is reached when the SC agrees, grounded on the report of the EWG, that there's sufficient scientific agreement on the specialized issues for the Technical Document to do to the coming stage of nonsupervisory discussion. This agreement is verified by at least one of the SC members for each of the six ICH parties subscribing their assent.

- Step 2b: Relinquishment of draft Guideline by Regulatory Parties On the base of the Technical Document, the three ICH nonsupervisory parties will take the conduct they suppose necessary to develop the draft Guideline.
- Step 3: Regulatory discussion and Discussion Step.
- Step 4: Relinquishment of an ICH Harmonised triplex Guideline Step 4 is reached when the Steering Committee agrees that there's sufficient agreement on the draft Guideline. The Step 4 Final Document is inked- off by the SC signatories for the nonsupervisory parties of ICH as an ICH Harmonised triplex Guideline at Step 4 of the ICH process.
- Step 5:Perpetration having reached Step 4 the harmonised triplex Guideline moves incontinently to the final step of the process that's the nonsupervisory perpetration. This step is carried out according to the same public/ indigenous procedures that apply to other indigenous nonsupervisory guidelines and conditions, in the European Union, Japan and the USA.

2. Q & A Procedure

The Q&A Procedure is followed when fresh guidance is considered necessary to help the interpretation of certain ICH harmonised triplex guidelines and insure a smooth and harmonious perpetration in the ICH regions and beyond.

The fresh guidance is generally developed in the form of Questions and Answers" Q&A s". The procedure is initiated with the countersign by the SC of a Concept Paper. In the case of major perpetration conditioning, the Steering Committee may also consider the need for Business Plan. A perpetration Working Group(IWG) with class as specified by the Concept Paper is latterly established.[16] The Q&A Procedure is driven by questions issues raised by stakeholders, which serve as the base for the development of model questions for which standard answers are developed. To help the process, stakeholders are frequently invited via the ICH website to submit their questions on a specific guideline.

The IWG works to reach agreement on a draft Q&A document and makes a recommendation to the SC on whether the document should be a Step 2b draft Document published for discussion or a Step 4 final Document published as final without discussion. This recommendation is grounded on the position of information handed by the answers. The document also follows the normal path of a Step 2/ Step 4 Document as per the Formal ICH Procedure.

3. Revision Procedure

The Revision Procedure is followed either in cases where the scientific/ specialized content of a being ICH Guideline is no longer over- to- date or valid, or in cases where there's new information to be added with no emendations to the being ICH Guideline necessary. In the case of the ultimate, the new information can be added in the form of an Addendum or an Addition to the Guideline in question. The procedure is initiated with the countersign by the SC of a Concept Paper. For variations a Business Plan isn't necessary. An Expert Working Group (EWG) with class as specified by the Concept Paper is latterly established.[17]

The Revision Procedure is nearly identical to the Formal ICH Procedure i.e., 5 ICH way. The only difference is that the final outgrowth is a revised interpretation of a being guideline, rather than a new guideline.

The modification of a guideline is designated by the letter R1 after the usual denotation of the guideline. When a guideline is revised further than formerly, the document will be named R2, R3, R4, etc at each new modification. In cases where an Addendum or Annex has been developed, upon reaching Step 4 the Addendum or Annex is typically added to the being guideline performing in a revised guideline.

4. Maintenance Procedure

The conservation Procedure is presently applicable only for changes to the Q3C Guideline contaminations Residual Detergents and M2 Recommendations. In each case the procedure is used when there's new information to be added or the scientific/ specialized content is out-of- date or no longer valid.[18]

A. Conservation Procedure for Q3C Guideline contaminations: Residual Detergents the Conservation Procedure for Q3C is followed when there's an offer of a" permitted diurnal exposure"(PDE) for a new detergent or a revised PDE for a formerly classified detergent. The procedure was harmonised by all six parties in Brussels on February 2002 and is analogous to the Formal ICH Procedure in that it follows the 5 ICH way (13- 14). Updates to the Addenda of the Q3C guidelines are considered as variations to the Q3C guideline and are designated by the letter R.

B. Conservation Procedure for M2 Recommendations

Due to the information technology (IT) nature of the M2 EWG's work on electronic norms for the Transfer of Regulatory Information(ESTRI), some of their conditioning affect in Recommendations. These Recommendations don't suffer the formal ICH step process, so as to allow for flexible change as both wisdom, and technologies evolve. They're agreed in the EWG, inked by all parties of the EWG, and are approved and inked off by the ICH Steering Committee.[18]

The Future of ICH

ICH has completed an important phase. crucial guidelines are now being enforced in the areas of Efficacy, Quality and Safety in the three ICH regions. The association has established a conservation procedure to ensure that the guidelines continue to reflect the rearmost scientific developments and stylish practice. These conservation conditioning are essential to the future of ICH, and to ensure that harmonisation continues. Several further ambitious guidelines are under development, similar as Good Manufacturing Practice (GMP) for Active Pharmaceutical constituents (APIs), Pharmacopoeias Harmonisation. The Common Technical Document and its electronic counterpart will be available in lower than two times, both set to change procedures for nonsupervisory dossier submission significantly. The association has honoured the significance of making available information on the ICH process and guidelines to non-ICH regions with the establishment of the Global Cooperation Group. As well as making information available, the group will act as a resource in the understanding, and indeed acceptance, of numerous of the guidelines.[19]

Other motifs that may now come to the fore are those similar as the Harmonisation of Regulatory Review Procedures. While the guidelines set a common standard for development, there's no congruity in review. By promoting lesser commerce between the competent authorities, similar that there's further translucency in the review process, it's a reasonable stopgap that a common standard of review will be achieved. Such a development is commodity that the assiduity should laboriously encourage through the ICH forum, as the benefits would be significant.

DISCUSSION

Eventually, ICH looks to the future. It has established a structure to maintain the guidelines, and at the same time is looking to make available information on the ICH process and guidelines to non-ICH regions with the establishment of the Global Cooperation Group. As

well as making information available, the group will act as a resource in the understanding, and indeed acceptance, of numerous of the guidelines. From an assiduity perspective globalization is arguably the most important issue it faces, and the capability of these guidelines to effect intra-company globalization is a hand of ICH that cannot be ignored. This is formerly passing within companies. Its value has not been quantified; still, the companies suitable to embrace these principles moment will be the world leader's hereafter. Companies who fail to see the value of harmonisation — the value that's formerly being felt by the scientists carrying out the development, and the value that's yet to be realized in the full medicine development cycle — will be left at the starting line of the assiduity's globalization race.

REFERENCES

1. ICH the need to harmonise [Online]. [cited 2014 May 02]; Available from: URL:http://www.ich.org/about/history.html
2. ICH harmonise for better health vision [Online]. [cited 2014 Apr 25]; Available from: URL:http://www.ich.org.about/vision.html
3. ICH steering committee [Online]. [cited 2014 Apr 25]; Available from: URL: http://www.ich.org/about/organisation -of-ich/steering.html
4. ICH global cooperation [Online]. [cited 2014 Apr 28]; Available from: URL: http://www.ich.org/about/organisation -of-ich/coopgroup.html
5. Medical dictionary for regulatory activities management board [Online]. [cited 2014 May 02]; Available from: URL: http://www.ich.org/about/organisation -of-ich/meddra.html
6. Secretariat ICH for better health [Online]. [cited 2014 Apr 29]; Available from: URL: http://http://www.ich.org/about/organegation-of-ich/secretariat.html
7. Coordinators organisation of ICH [Online]. [cited 2014 May 01]; Available from URL: http://www.ich.org/about/organisation -of-ich/coordinators.html
8. Working groups of ICH organisation [Online]. [cited 2014 Apr 24]; Available from: URL://http://www.ich.org/about/organisati on-of-ich/working-groups.html
9. Process of ICH harmonisation [Online]. [cited 2014 Apr 28]; Available from: URL: http://www.ich.org/about/process-ofharmonisation/formalproc.html
10. International Harmonisation of the Regulation of New Pharmaceutical Drugs [Online]. [cited 2014 Apr 30]; Available from: URL: http://www.whpapsf.ca/en/documents/who_benefits.html

11. Working groups of ICH organisation [Online]. [cited 2014 Apr 24]; Available from: URL://http://www.ich.org/about/organisati on-of-ich/working-groups.html
12. Patel S., & Apte M. A Review on Significances of Impurity Profiling. Research Journal of Pharmaceutical Dosage Forms and Technology, 2016; 8(1): 31-36.
13. Misra Bishal, A. Thakur, and P. P. Mahata. "Pharmaceutical Impurities: a review." IJPC, 2015; 5.07: 232-239.
14. Dwivedi A.H., Pillai S.G. and Patni N., Impurities in Pharmaceutical Industries: A Burning Issue. Int J chem tech Appl, 2010; 2(2): 113-125.
15. ICH Guidelines, available on https://www.ich.org/page/ich-guidelines
16. Q&A procedure of ICH harmonisation [Online]. [cited 2014 May 01]; Available from: URL: http://www.ich.org/about/process-ofharmonisation/ qa-procedure.html
17. Revision procedure ICH harmonisation [Online]. [cited 2014 Apr 28]; Available from: URL://http://www.ich.org/about/process-of-harmonisation/revisionprocedure.html
18. Maintenance procedure of ICH harmonisation [Online]. [cited 2014 Apr 24]; Available from: URL: http://http://www.ich.org/about/process-of-harmonisation/maintenanceprocedure.html
19. Molzon Justina A., US Food and Drug Admiration, The value and benefits of ICH to drug regularity authorities- Advance harmonisation for better health.